Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Insight on Practice Changing From IGCS 2021 Informing Treatment for Endometrial, Ovarian, and Cervical Cancer

The 2021 SGO Virtual Annual Meeting, 19-25 March 2021, in Seattle, Washington, USA; The 2021 ASCO Annual Meeting, 4-8 June 2021, in Chicago, Illinois, USA; The 2021 IGCS Meeting, 30 August - 2 September, in Rome, Italy; The ESMO 2021 Annual Congress, 17-21 September 2021, in Paris, France; The 2021 ESGO Conference, 23-26 October 2021, in Prague, Czech Republic
In this podcast episode, listen to Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, discuss practice‑changing data for gynecologic cancers presented at the virtual IGCS 2021 annual meeting, including novel data for single-agent and combination immunotherapy in patients with endometrial and cervical cancers, subanalyzes of exceptional responders to PARP inhibitors in ARIEL3, and timing for initiation of PARP inhibitor maintenance from the NORA trial.
person default
Alexandra Leary, MD, PhD
Domenica Lorusso, MD, PhD
Released: September 21, 2021

In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide expert insights on practice changing data from IGCS 2021 presented for endometrial, ovarian, and cervical cancers regarding:

  • A subgroup analysis from phase III KEYNOTE-775 evaluating lenvatinib plus pembrolizumab efficacy in patients with advanced endometrial cancer and dMMR status
  • A subgroup analysis from the phase I GARNET trial─cohorts A1 and A2─in patients with advanced endometrial cancer who had received either 1 or ≥2 prior lines of therapy
  • Data from the TOTEM trial reporting survival outcomes for patients undergoing intensive vs minimalist follow-up in following treatment for endometrial cancer
  • An exploratory analysis from the phase III ARIEL3 trial evaluating characteristics of patients with ovarian cancer with exceptional benefit from rucaparib
  • A post hoc analysis from the phase III NORA trial assessing efficacy of starting PARP inhibitor maintenance following either ≤4 vs >4 cycles of platinum-based chemotherapy
  • Highly anticipated results from the phase III EMPOWER-CERVICAL 1 trial of cemiplimab vs investigator’s choice chemotherapy in women with cervical cancer

Information on this Educational Activity

Faculty

Alexandra Leary, MD, PhD

Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Paris, France

Alexandra Leary, MD, PhD, has disclosed that she has received funds for research support from Ability, AstraZeneca, Clovis, GlaxoSmithKline, MSD, and Tesaro; consulting fees from Ability, AstraZeneca, Biocad, Clovis, Merck Serono (paid to her institution), MSD, Seattle Genetics, Tesaro, and Zentalis; and other financial or material support from AstraZeneca, Clovis, GlaxoSmithKline, and Tesaro.
Domenica Lorusso, MD, PhD

Associate Professor
Gynecologic Oncology Department
Clinical Research Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy

Domenica Lorusso, MD, PhD, has disclosed that she has received consulting fees from Amgen, AstraZeneca, Clovis, GlaxoSmithKline, MSD, and Pharmamar; fees for non-CME/CE services from MSD; and other financial or material support from AstraZeneca, Clovis, GlaxoSmithKline, and Pharmamar.

Program Medium

This program has been made available online.

Acknowledgements

This educational activity is supported by an educational grant from
GlaxoSmithKline

Related Content

From Clinical Care Options (CCO), download a PDF featuring expert discussion on patient cases on ovarian cancer treatment

Nicoletta Colombo, MD person default Philipp Harter, MD, PhD person default Alexandra Leary, MD, PhD Released: October 19, 2021

A downloadable slideset from Clinical Care Options (CCO) developed by 3 expert faculty on the expert management of ovarian cancer using PARP inhibitors.

Ursula Matulonis, MD
Program Director
Robert L. Coleman, MD, FACOG, FACS person default Kathleen Moore, MD
Released: October 18, 2021

Expert podcast on key data and current FDA approvals of first-generation TRK inhibitors with Dr. George Demetri and Dr. Alexander Drilon, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue